Search clinical trials for: Pharmacokinetics of MT-8554

Total 427831 results

Mitsubishi Tanabe Pharma Corporation

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of MT-8554 in Female Subjects Experiencing Vasomotor Symptoms

Vasomotor Symptoms

Germany
Mitsubishi Tanabe Pharma America Inc.

Completed

MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal Women

Menopause Hot Flashes

United States
Mitsubishi Tanabe Pharma Corporation

Completed

Study to Assess the Efficacy, Safety and Tolerability of MT- 8554 in Subjects With Painful Diabetic Peripheral Neuropathy

Painful Diabetic Peripheral Neuropathy

Germany, Hungary, Poland
Mitsubishi Tanabe Pharma America Inc.

Completed

Definitive QT Study With MT-8554 (MT-8554 DQT)

Healthy Volunteer

United Kingdom
Mitsubishi Tanabe Pharma Corporation

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-8554 in Healthy Subjects

Healthy

United Kingdom
Mitsubishi Tanabe Pharma America Inc.

Completed

Long-term Safety and Efficacy Study of MT-8554 in Postmenopausal Women With Vasomotor Symptoms

Vasomotor Symptoms (VMS)

United States
Mitsubishi Tanabe Pharma Corporation

Completed

Exploratory Study of MT-8554 in Subjects With Painful Diabetic Peripheral Neuropathy

Painful Diabetic Peripheral Neuropathy

Japan
Mitsubishi Tanabe Pharma America Inc.

Completed

Mass Balance Study With MT-8554 (MT-8554 MB)

Healthy Volunteer

United Kingdom
Mitsubishi Tanabe Pharma Corporation

Completed

A Study to Investigate the Pharmacodynamic Effect of Single Doses of MT-8554 in Healthy Subjects

Healthy

United Kingdom
Mitsubishi Tanabe Pharma Corporation

Completed

A Study to Investigate the Effect of MT-8554 on the Pharmacokinetics of Simvastatin and Rosuvastatin in Healthy Subjects

Healthy

United Kingdom
Mitsubishi Tanabe Pharma Corporation

Completed

Safety, Tolerability and Pharmacokinetic Study of MT-3995 in Subjects With Diabetic Nephropathy

Diabetic Nephropathy

Japan
Mitsubishi Tanabe Pharma America Inc.

Terminated

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-6345 in Healthy Subjects

Healthy

United Kingdom
Mitsubishi Tanabe Pharma Corporation

Completed

Comparative Oral Bioavailability Study of MT-1303

Relapsing-remitting Multiple Sclerosis

United Kingdom
Molecular Templates, Inc.

Terminated

Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL (MT-3724NHL001)

Leukemia, Lymphocytic, Chronic, B-Cell | Diffuse Large B Cell Lymphoma | Blood Cancer | Hematological Malignancy | Small Lymphocytic Leukemia | Non-Hodgkin's B-cell Lymphoma

United States, Canada, Georgia, Belarus, Spain, Israel, Moldova, Republic of, Poland, Serbia, Ukraine
Mitsubishi Tanabe Pharma America Inc.

Completed

Safety and Pharmacokinetics Study of MT-3921 in Spinal Cord Injury

Spinal Cord Injury

United States
Mitsubishi Tanabe Pharma Corporation

Completed

An Extended Treatment Study of MT-3995 in Patients With Diabetic Nephropathy

Diabetic Nephropathy

Japan
Bausch Health Americas, Inc.

Active, not recruiting

Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis

Ulcerative Colitis

United States
Mitsubishi Tanabe Pharma Corporation

Completed

Extension Study of MT-1303

Relapsing-remitting Multiple Sclerosis

Belgium, Bulgaria, Canada, Croatia, Czech Republic, Finland, Germany, Hungary, Italy, Lithuania, Poland, Russian Federation, Serbia, Spain, Turkey, Ukraine, United Kingdom
Mitsubishi Tanabe Pharma America Inc.

Completed

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria or X-Linked Protoporphyria

EPP | XLP

Spain, United States, Germany, Norway, Italy, Australia, Canada, Japan, Sweden, United Kingdom
Mitsubishi Tanabe Pharma Corporation

Completed

Dose-finding Study of MT-1303

Relapsing-remitting Multiple Sclerosis

Croatia, Bulgaria, Czech Republic, Italy, Russian Federation, Spain, United Kingdom, Germany, Lithuania, Poland, Belgium, Hungary, Serbia, Finland, Ukraine, Switzerland, Canada, Turkey
Mitsubishi Tanabe Pharma Corporation

Completed

Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Plaque Psoriasis

Bulgaria, Russian Federation, Estonia, Hungary, Latvia, Poland, Ukraine, Germany
University of Nebraska
Northeast Nebraska Public Health Department

Completed

Engaging Rural Men With Mobile Technologies for Weight Loss

Weight Loss

United States
Mitsubishi Tanabe Pharma Corporation

Completed

Exploratory Study of MT-1303 in Systemic Lupus Erythematosus Patients

Systemic Lupus Erythematosus

Japan
Chang Gung Memorial Hospital
National Science Council, Taiwan

Completed

Effects and Mechanisms of Treatment Intensity of Mirror Therapy in Patients With Subacute Stroke

Cerebrovascular Accident

Taiwan
Chang Gung Memorial Hospital

Unknown

Augmenting the Effects of Mirror Therapy for Stroke Rehabilitation by tDCS

Cerebrovascular Accident

Taiwan
Medicago
Mitsubishi Tanabe Pharma Corporation

Terminated

Safety Immunogenicity Study of MT-2766 in Japanese Adults（COVID-19）

SARS-CoV-2 Infection

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria

Diabetic Nephropathy

Lithuania, Romania, Bulgaria, Hungary, Slovakia
Mitsubishi Tanabe Pharma Corporation

Completed

Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety Study of MT-1303 in Subjects With Crohn's Disease

Crohn's Disease

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety of MT-3995 in Patients With Diabetic Nephropathy

Diabetic Nephropathy

Japan
University of Miami

Completed

Mindfulness Training for Seniors

Well Aging

United States
Mitsubishi Tanabe Pharma America Inc.

Completed

Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function

Mild and Moderate Hepatic Impairment

United States
Mitsubishi Tanabe Pharma Corporation

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of MT-1303 in Subjects With Inflammatory Bowel Disease

Inflammatory Bowel Disease

United Kingdom
Renrong Wu

Completed

MT Combined With XKSA for Depressive Symptoms During COVID-19

Depression, Anxiety

China
Quanta System, S.p.A.

Unknown

Effect of Hybrid Laser 10600+1540 nm on GSM

Vaginal Atrophy | Genitourinary Disease

Spain
International Hellenic University

Completed

Manual Therapy Plus Pain Neuroscience Education With Integrated Motivational Interviewing in Individuals With Non-Specific Chronic Low Back Pain

Non-specific Chronic Low Back Pain

Greece
Mitsubishi Tanabe Pharma Corporation

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-7117 in Healthy Subjects

Healthy

United Kingdom
University of Valencia
Hospital de la Ribera

Unknown

Neuroscience Education on Osteoarthritis

Osteoarthritis

Spain
Mitsubishi Tanabe Pharma Corporation

Completed

A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria and Moderately Decreased GFR

Diabetic Nephropathy

Romania, Bulgaria, Hungary, Poland, Czech Republic, Slovakia
NORCE Norwegian Research Centre AS
King's College London; Oslo University Hospital; Meir Medical Center; Haukeland... and other collaborators

Completed

Longitudinal Study of Music Therapy's Effectiveness for Premature Infants and Their Caregivers (LongSTEP)

Preterm Birth

Norway, Israel, Argentina, Colombia, Poland
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Efficacy and Tolerability of Pancrelipase Microtablet (MT) Capsules for the Treatment of Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency

Malabsorption Syndromes | Cystic Fibrosis | Steatorrhea | Exocrine Pancreatic Insufficiency

United States, Canada
Peking University Third Hospital

Completed

Analysis the Positive Rate of Tumor Markers Among Physical Examination Population

Tumor

China
The Miriam Hospital
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Mind Your Heart Study

Medication Non-adherence

United States
Mitsubishi Tanabe Pharma Corporation

Completed

Safety and Immunogenicity of MT-5625 in Healthy Adults, Toddlers and Infants

Healthy

Australia, South Africa
Mitsubishi Tanabe Pharma Corporation

Completed

Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 With Single, Escalating Doses in Healthy Subjects

Dyslipidemia

United Kingdom
Banc de Sang i Teixits
European Regional Development Fund; Ministerio de Sanidad, Servicios Sociales... and other collaborators

Completed

Mesenchymal Stem Cells in Osteonecrosis of the Femoral Head

Avascular Necrosis of Femur Head

Spain
Brown University
University of Pittsburgh Medical Center; Richard King Mellon Foundation

Completed

A Mindfulness Approach to UA for Afro-descendants

Stress | Anxiety

United States
Toray Industries, Inc

Terminated

Efficacy and Safety of MT-9938 for Treatment of Uremic Pruritus in Subjects With End-stage Renal Disease Receiving Hemodialysis

Uremic Pruritus

United States
Marker Therapeutics, Inc.

Recruiting

Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma (APOLLO)

Non Hodgkin Lymphoma | Non-Hodgkin Lymphoma, Adult | Non-Hodgkin Lymphoma, Refractory | Non-Hodgkin Lymphoma, Relapsed

United States
Assistance Publique Hopitaux De Marseille

Completed

Beta-thalassemia and Microparticles

Thalassemia Major (TM) | Thalassemia Intermedia (TI) | Microparticles (MP)Originating From Platelets, Endothelial Cells and Monocytes

France
Mitsubishi Tanabe Pharma America Inc.

Completed

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria

Erythropoietic Protoporphyria (EPP)

United States

Search clinical trials for: Pharmacokinetics of MT-8554

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations